Literature DB >> 11583351

Clinical management of the neurourological syndrome associated with multiple sclerosis and correlations to grade of the disease.

G A Barbalias1, E N Liatsikos, C Passakos, D Barbalias, G Sakelaropoulos.   

Abstract

PURPOSE: In this study a detailed clinical management is presented as it is practiced in our department, and possible correlations between grade of the disease and therapeutic responses are examined.
MATERIALS AND METHODS: One hundred and ten patients were consecutively and prospectively studied with a clinical syndrome of MS, ranging in age from 32 to 65 years of age. Clinical diagnosis of the voiding dysfunction associated with MS was classified as a malfunction causing either problems of bladder evacuation, or storage, or a combination of both. Therapeutic responses of the voiding dysfunction were correlated with grade of the disease. Mean follow up period was 54 months.
RESULTS: All patients were initially managed in a conservative way avoiding surgical procedures and following primarily pharmacologic treatment, because of the quite common reversibility of MS. A possible correlation of response to treatment according to grade of the disease was studied. There was significant difference in the response to drug treatment among patients of different grades favoring grade 1 patients with both storage and evacuation voiding dysfunction.
CONCLUSIONS: Our suggested treatment has secured the conversion of a high pressure into a low pressure vesicourethral system, thus obviating possible risk factors for the upper urinary tract and the bladder itself. Therapeutic responses were dependent upon the grade of the disease.

Entities:  

Mesh:

Year:  2001        PMID: 11583351     DOI: 10.1023/a:1017553200693

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  12 in total

Review 1.  Urodynamics and multiple sclerosis.

Authors:  J L Hinson; T B Boone
Journal:  Urol Clin North Am       Date:  1996-08       Impact factor: 2.241

2.  Urinary tract dysfunction in multiple sclerosis: is there a relation with disease-related parameters?

Authors:  D Porru; G Campus; A Garau; M Sorgia; A C Pau; G Spinici; M P Pischedda; M G Marrosu; R M Scarpa; E Usai
Journal:  Spinal Cord       Date:  1997-01       Impact factor: 2.772

3.  Detrusor-external sphincter dyssynergia in men with multiple sclerosis: an ominous urologic condition.

Authors:  J G Blaivas; G A Barbalias
Journal:  J Urol       Date:  1984-01       Impact factor: 7.450

4.  Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis.

Authors:  C D Betts; M T D'Mellow; C J Fowler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-03       Impact factor: 10.154

Review 5.  Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. Committee of the European Study Group of SUDIMS (Sexual and Urological Disorders in Multiple Sclerosis)

Authors:  C J Fowler; P E van Kerrebroeck; A Nordenbo; H Van Poppel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

6.  Detrusor-external sphincter dyssynergia.

Authors:  J G Blaivas; H P Sinha; A A Zayed; K B Labib
Journal:  J Urol       Date:  1981-04       Impact factor: 7.450

7.  Detrusor-external sphincter dyssynergia: a detailed electromyographic study.

Authors:  J G Blaivas; H P Sinha; A A Zayed; K B Labib
Journal:  J Urol       Date:  1981-04       Impact factor: 7.450

8.  [Intermittent self-catheterization in multiple sclerosis].

Authors:  E Luoto; M Jussilainen; S Sandell
Journal:  Sairaanhoitaja       Date:  1993

9.  Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis.

Authors:  E L Koldewijn; O R Hommes; W A Lemmens; F M Debruyne; P E van Kerrebroeck
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450

10.  Fate of the upper urinary tract in multiple sclerosis.

Authors:  N G Kasabian; I Krause; W E Brown; Z Khan; H M Nagler
Journal:  Neurourol Urodyn       Date:  1995       Impact factor: 2.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.